RABOZ-LSP is a specialized pharmaceutical formulation combining Rabeprazole Sodium 20 mg and Levosulpiride 75 mg SR, designed explicitly for the management and treatment of complex gastrointestinal disorders including diabetic gastroparesis, irritable bowel syndrome (IBS), gastric ulcers, gastroesophageal reflux disease (GERD), and duodenal ulcers. This dual-action formula offers a potent proton pump inhibitor (PPI) alongside a highly effective prokinetic agent, delivering comprehensive relief by reducing gastric acid secretion and enhancing gastrointestinal motility. With an extended-release mechanism, Levosulpiride promotes accelerated gastric and gallbladder emptying through D2 dopamine receptor antagonism and serotonin 5HT4 receptor agonism, providing superior symptom reduction compared to other prokinetics such as domperidone. RABOZ-LSP is clinically validated for prolonged safety and efficacy, making it an ideal choice for long-term maintenance therapy, especially for reflux esophagitis and other chronic GI ailments. Businesses and healthcare providers can rely on RABOZ-LSP to offer patients improved digestive comfort, effective symptom management, and reliable therapeutic outcomes.
Key Features
| Features | Description |
|---|---|
| Active Ingredients | Rabeprazole Sodium 20 mg + Levosulpiride 75 mg SR |
| Mechanism of Action | Potent PPI (acid reduction) combined with dual-action prokinetic enhancing gastric motility |
| Indications | Diabetic gastroparesis, IBS, Gastric ulcer, GERD, Duodenal ulcer |
| Prokinetic Benefits | Accelerates gastric and gallbladder emptying via D2 antagonism and 5HT4 agonism |
| Efficacy | Superior symptom relief compared to other prokinetics like domperidone |
| Safety Profile | Suitable and safe for long-term maintenance therapy in reflux esophagitis |
| Dosage Form | Sustained Release Capsule |
| Therapeutic Advantage | Combines acid suppression with motility enhancement for comprehensive GI care |
| Clinical Validation | Backed by studies demonstrating effectiveness and safety in GI disorders |
| Attributes | Description |
|---|---|
| Generic Name | Rabeprazole Sodium + Levosulpiride |
| Dosage Strength | Rabeprazole Sodium 20 mg, Levosulpiride 75 mg SR |
| Dosage Form | Capsule (Sustained Release) |
| Indications | Diabetic gastroparesis, IBS, Gastric and duodenal ulcers, GERD |
| Pharmacological Class | Proton Pump Inhibitor (PPI) and Prokinetic Agent |
| Release Mechanism | Sustained release for prolonged action |
| Administration Route | Oral |
| Treatment Duration | Approved for long-term maintenance therapy |
| Regulatory Status | Approved GI regulator and PPI combination |
| Storage | Store in a cool, dry place away from direct sunlight |
*Disclaimer: The above description has been AI-generated and has not been audited or verified for accuracy. It is recommended to verify product details independently before making any purchasing decisions.
RABOZ-LSP contains Levosulpiride 75 mg SR which acts as a dopamine D2 receptor antagonist and serotonin 5HT4 receptor agonist, accelerating gastric and gallbladder emptying, thereby improving motility impaired by diabetic gastroparesis.
RABOZ-LSP combines Rabeprazole, a potent PPI known for minimal long-term side effects, with Levosulpiride’s prokinetic properties, allowing prolonged therapy that effectively controls acid reflux while enhancing GI motility, reducing risks of chronic GERD complications.
Yes, clinical evidence indicates that Levosulpiride in RABOZ-LSP offers superior symptom control for dyspepsia compared to domperidone, due to its dual receptor activity and sustained release formulation.
RABOZ-LSP’s formulation is effective against acid-related ulcers due to Rabeprazole’s acid suppression, while Levosulpiride addresses motility and dyspeptic symptoms common in IBS, making it suitable for both ulcer treatment and managing IBS symptoms.
The sustained-release (SR) formulation ensures a steady plasma concentration of Levosulpiride, leading to prolonged prokinetic effects that enhance gastric emptying and symptom control with once-daily dosing, improving patient compliance.
RABOZ-LSP stands as the definitive solution for gastrointestinal challenges like diabetic gastroparesis, IBS, gastric ulcer, GERD, and duodenal ulcer. Our comprehensive formula is meticulously crafted to provide unparalleled relief and healing, backed by proven efficacy in addressing these conditions. Embrace confidence in managing GI health with RABOZ-LSP, your strategic ally in delivering effective relief and comfort. Join the ranks of satisfied individuals and businesses relying on RABOZ-LSP for optimal GI wellness and seamless digestive care.
FOR G.I. PROBLEMS LIKE
• Diabetic gastroparesis IBS
• Gastric ulcer & GERD
• Duodenal ulcer
Raboz-LSP
Rabeprazole Sodium 20 mg + Levosulpiride 75 mg SR Cap.
The Combined Synergy of APPROVED GI Regulator & Potent PPI
PROLONGED SAFETY -Effective as a long te-rm Maintenance Therapy Safe and effective for long-term maintenance therapy of reflux esophagitis
Intern Med. 2011;50(11)
Levosulpiride Remarkably Superior to Domperidone & Other Prokinetics
Exerts prokinetic action through dual mechanism:
1) as a D(2) dopamine receptor antagonist and 2) as a serotonin 5HT(4) receptor agonist,
At a dosage of 75 mg SR daily, levosulpiride accelerates gastric and gallbladder emptying More effective in reducing symptoms of dyspepsia, as compared to other dopamine antagonists*
*Gastroenterol Hepatol. 2010 Oct;33(8)
Raboz-LSP
The Dependable PPI with Long Standing Prokinetic
Inclusive of all taxes
You Save: 0
Jaipur , India
Brand Owner, Distributor, Wholesaler, Women Entrepreneur
